Investigation
SOMAÍ Pharmaceuticals and Universidade Lusófona collaborate on scientific publication on the 'entourage' effect
The medical cannabis industry continues to evolve, with research paving the way for innovative therapeutic applications. SOMAÍ Pharmaceuticals, a leading EU-GMP certified multinational operator, is taking significant steps in advancing the science of medicinal cannabis. In collaboration with Lusophone University (UL) and yours Center for Research in Biosciences and Health Technologies (CBIOS), SOMAÍ recently celebrated the publication of its extensive study, “The Entourage Effect in Medicinal Cannabis Products: A Comprehensive Review”, in the prestigious journal Pharmaceuticals (MDPI).
This research underscores SOMAÍ’s commitment to exploring the entourage effect – a phenomenon in which cannabinoids such as Delta9-THC and CBD interact synergistically with terpenes and other minor cannabinoids, enhancing their therapeutic efficacy.
The meaning of the entourage effect in medical cannabis
The entourage effect has become a focal point in medical cannabis research. It highlights the potential of a multi-compound approach in which secondary metabolites, such as terpenes and minor cannabinoids, amplify the effects of primary compounds, such as THC and CBD. This synergy not only enhances therapeutic benefits but also has the potential to minimize adverse effects associated with the use of cannabinoids alone.
Despite its promise, achieving consistent results with the entourage effect presents challenges. Variability in cannabinoid and terpene profiles, coupled with the complexities of maintaining product quality across batches, remains a key hurdle in clinical applications. SOMAÍ Pharmaceuticals is addressing these challenges through its advanced research and technologies.
SOMAÍ Pharmaceuticals and Lusófona University: A partnership in innovation
SOMAÍ’s collaboration with Universidade Lusófona and CBIOS represents a pioneering effort to unlock the full potential of cannabis formulations. This partnership focuses on the integration of minor cannabinoids and terpenes into medicinal products, with the goal of delivering accurate and reliable therapeutic results.
A central goal of this research is to standardize cannabinoid and terpene dosages, ensuring a consistent cause-and-effect relationship between administration and clinical outcomes. Precision is essential in medical cannabis, where individualized patient care and predictable outcomes are key to success.
“At SOMAÍ, science is the cornerstone of everything we do”, said Michael Sassano, CEO of SOMAÍ Pharmaceuticals. “Our commitment to developing proprietary terpene formulations and exploring the role of minor cannabinoids underscores our dedication to advancing medical cannabis solutions. Our Essentials, Origins and Senses product lines reflect this commitment to innovation.”
Use of advanced analytical techniques for quality assurance
To overcome consistency challenges, SOMAÍ employs state-of-the-art High Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC) profiling techniques. These technologies ensure that cannabinoid and terpene concentrations remain stable across product batches.
This rigorous quality control allows SOMAÍ to provide medicinal cannabis products that meet the highest standards of reliability and efficacy. By supporting solid research into the interaction between cannabinoids and terpenes, SOMAÍ is setting new benchmarks for the cannabis industry.
Driving scientific discovery
The collaboration with UL signifies SOMAÍ’s unwavering commitment to expanding scientific understanding of medicinal cannabis. Dr. Maria do Céu Costa, professor at Lusófona University, expressed her enthusiasm for the partnership, stating:
“Working with SOMAÍ Pharmaceuticals, a leader in the field of medicinal cannabis, inspires us to push the boundaries of research. Together, we are shaping the future of cannabis-based medicine and unlocking the transformative potential of terpenes and minor cannabinoids in improving therapeutic outcomes.”
This partnership exemplifies the importance of collaboration between academia and industry in advancing cannabis research and unlocking its full potential for patients around the world.
A Vision for the Future of Medicinal Cannabis
SOMAÍ Pharmaceuticals is committed to revolutionizing cannabis-based therapies by focusing on the entourage effect. The company’s dedication to innovation, quality and scientific excellence places it at the forefront of the industry.
Through partnerships such as the one established with Lusófona University, SOMAÍ aims to bring consistent and reliable medicinal cannabis products to the market. These efforts not only improve therapeutic options for patients, but also contribute to a deeper understanding of the complex chemistry of cannabis.
By harnessing the power of the entourage effect, SOMAÍ Pharmaceuticals is paving the way for a future where medicinal cannabis reaches its full potential, offering safer, more effective treatments for a wide range of conditions.
SOMAÍ Pharmaceuticals’ research, combined with its dedication to quality and innovation, underscores its leadership in the field of medical cannabis. As the industry evolves, SOMAÍ’s contributions will undoubtedly play a key role in shaping the next generation of cannabis-based therapies.
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!
With a professional background in CAD technical drawing (2D and 3D), João Xabregas is an activist and advocate for all uses and applications of cannabis. He discovered and entered the world of cannabis during his youth, where he developed a special interest in the cultivation of the plant, which led him on a journey of self-learning through the world of cannabis that continues to this day. His adventures linked to cannabis cultivation began with the same goal as many others: to be able to guarantee the quality and eliminate any possible risks to his health of what he consumed, as well as to avoid any type of dependence on the illicit market. However, he quickly began to view the world of cannabis and everything related to it with a very different perspective. He admits the enormous passion he has for the most persecuted plant in the world and about which he is always willing to write and have a good conversation.
Thailand has found a solution where European countries still see a problem.
Reading Time: 13 minutes On my second trip to Thailand, I was once again pleasantly surprised. After visiting several...
The Royal Thai Embassy in Tokyo promotes "Adapting International Hemp to Japan's New Regulations"
Reading Time: 3 minutes The International Business Meeting “Adapting the International Market...” will take place tomorrow, November 13, 2025.
Portugal: Infarmed updates lists and removes licenses from two more medicinal cannabis companies.
Reading Time: 2 minutes. Infarmed has updated the public list of entities licensed for activities with medicinal cannabis in Portugal. The...
Portocanna strengthens its Hexacan portfolio with a new sublingual solution containing 20% THC.
Reading Time: 2 minutes. The Portuguese company Portocanna announced the launch of Hexacan® Hexa 01 Cannabis Oil Extract THC 20%,...
Cypress Hill confirmed for Rock in Rio Lisboa 2026
Reading Time: 2 minutes. The legendary American band Cypress Hill, whose hits "Insane in the Brain" and "Hits from the Bong"...
USA: Green Thumb Industries workers secure collective agreement after 45-day strike.
Reading Time: < 1 minute Workers at Green Thumb Industries, one of the largest multi-state cannabis companies in the United States...
Switzerland: Pacrim takes control of Medropharm and prepares for a new phase of expansion in medicinal cannabis.
Reading Time: 2 minutes. Pacrim has acquired two-thirds of the Swiss company Medropharm, thus gaining control of the company and its operations.
South Africa: Researchers discover rare phenolic compounds in cannabis leaves.
Reading Time: 4 minutes. Researchers at Stellenbosch University in South Africa have discovered that flavoalkaloids are produced in the leaves of the plant...
Covilhã – Dismantling of two cannabis greenhouses
Reading Time: < 1 minute The Castelo Branco Territorial Command, through the Criminal Investigation Unit (NIC) of Covilhã, in...
Tokyo will host the Japan International Hemp Expo on November 14th and 15th, 2025.
Reading Time: 4 minutes. For the first time since the legal reform, Japan opens its doors to the global hemp industry...
